Skip to main content
30 September, 2020

PFS Partner Hyris Secures UK Triumph with Canadian Government 90-Minute COVID-19 Testing Megadeal

Hyris bCUBE based test kit is the only authorised medical device approved for human tests in Point of Care currently commercially available in Canada. Hyris Ltd. now focuses on supporting Canada in fully facing the new virus escalation.

(London, UK, Wednesday, September 30th, 2020).

The Government of Canada has issued a significant approval for PFS’ London based client Hyris for rapid Coronavirus testing, which will be deployed across the country as Hyris “bCUBE” has been approved for human tests by Health Canada scientists; as such, the bCUBE is the only authorised medical device, commercially available in Canada for diagnostic use related to COVID-19, which can provide a certified ‘point of care’ solution. The bCUBE adopts “gold standard” genetic sequences in line with CDC and WHO guidelines: it can provide human COVID-19 test results at the same level as a hospital laboratory, without the requirement for a lab, also reducing the time needed for diagnosis.

The technology features an Internet of Things (IoT) architecture, meaning it can easily be scaled at speed to help millions of people to receive a reliable Coronavirus test result in under 2 hours. Hyris says it can profoundly positively impact satellite healthcare facilities, communities and companies worldwide that are currently starved of access to this type of disruptive solution.

One time aspiring astronaut turned tech entrepreneur, Stefano Lo Priore, Founder & CEO at Hyris, said: “The greater London area is a global hub for Biotechnology and Finance, and we feel we are well-positioned with our local partners to support the worldwide expansion of our user network. This authorization from the Canadian Government is an important confirmation for us as well as for PFS, which has been a trusted partner in this adventure for several years.”

Lee Britton, CCO at PFS (a company of EML), explained: “It's an honour to stand with our High Tech partner Hyris and our good friend Stefano as he enables testing heroes across Canada, and soon here in Europe, to fight COVID with an invaluable diagnostic solution. As we continue to engage with all kinds of inspirational tech thought leaders requiring smart payment solutions, we never lose sight of the positive impact companies like Hyris can have on countries around the world, and closer to home. Soon, Stefano and his team will be live in more than 12 nations.''

In the future, thanks to its platform, Hyris believes the units will generate data that when analysed collectively, may give next-level insights into pandemic developments and feed into AI algorithms that could help to best manage a global response.

 

Read the full article HERE

Hyris signs a distribution agreement with GrowBIGogh

Hyris technology supports the fight against one of the world’s deadliest diseases, malaria.

Hyris fulfils its integration into Ulisse Biomed to give birth to a new international group ready to make its mark in the global biotech market.

Distribution agreement renewal with Biomol Laboratories, fostering the partnership in the field of personalised medicine

Hyris' signed a binding agreement for a reverse take-over, leading to a new integrated entity with Ulisse Biomed

Hyris' new onboarding programs support researchers and developers to launch testing kits.

Hyris Founder&CEO Stefano Lo Priore interviewed by Carter&Benson

Hyris and Singlabs signed a distributorship agreement for Singapore

Hyris and P.Intertrade Equipments signed a distributorship agreement for Thai market.

Hyris to participate to SIBioC 2022 in Genova, presenting Hyris marketplace approach for laboratory medicine